HRs of UACR within normal range associated with the prognosis of CKM patients at stages 2 and 3 in CRDS database.
| . | . | . | Unadjusted . | Model 1 . | Model 2 . | |||
|---|---|---|---|---|---|---|---|---|
| Outcome . | . | Events/n . | HR (95% CI) . | P value . | HR (95% CI) . | P value . | HR (95% CI) . | P value . |
| Progression to CKM stage 4 | Increase 1 mg/g | 1646/14 602 | 1.029 (1.023–1.036) | <.001 | 1.023 (1.016–1.029) | <.001 | 1.011 (1.004–1.018) | .002 |
| Increase 5 mg/g | 1.156 (1.120–1.193) | <.001 | 1.119 (1.083–1.155) | <.001 | 1.056 (1.021–1.092) | .002 | ||
| All-cause mortality | Increase 1 mg/g | 185/14 602 | 1.076 (1.058–1.095) | <.001 | 1.067 (1.048–1.086) | <.001 | 1.063 (1.043–1.083) | <.001 |
| Increase 5 mg/g | 1.445 (1.323–1.557) | <.001 | 1.382 (1.263–1.512) | <.001 | 1.357 (1.237–1.488) | <.001 | ||
| . | . | . | Unadjusted . | Model 1 . | Model 2 . | |||
|---|---|---|---|---|---|---|---|---|
| Outcome . | . | Events/n . | HR (95% CI) . | P value . | HR (95% CI) . | P value . | HR (95% CI) . | P value . |
| Progression to CKM stage 4 | Increase 1 mg/g | 1646/14 602 | 1.029 (1.023–1.036) | <.001 | 1.023 (1.016–1.029) | <.001 | 1.011 (1.004–1.018) | .002 |
| Increase 5 mg/g | 1.156 (1.120–1.193) | <.001 | 1.119 (1.083–1.155) | <.001 | 1.056 (1.021–1.092) | .002 | ||
| All-cause mortality | Increase 1 mg/g | 185/14 602 | 1.076 (1.058–1.095) | <.001 | 1.067 (1.048–1.086) | <.001 | 1.063 (1.043–1.083) | <.001 |
| Increase 5 mg/g | 1.445 (1.323–1.557) | <.001 | 1.382 (1.263–1.512) | <.001 | 1.357 (1.237–1.488) | <.001 | ||
Model 1 was adjusted by age and gender. Model 2 was adjusted by age, gender, hypertension, diabetes, non-HDL cholesterol, eGFR and administration of statins. UACR, urinary albumin-to-creatinine ratio.
HRs of UACR within normal range associated with the prognosis of CKM patients at stages 2 and 3 in CRDS database.
| . | . | . | Unadjusted . | Model 1 . | Model 2 . | |||
|---|---|---|---|---|---|---|---|---|
| Outcome . | . | Events/n . | HR (95% CI) . | P value . | HR (95% CI) . | P value . | HR (95% CI) . | P value . |
| Progression to CKM stage 4 | Increase 1 mg/g | 1646/14 602 | 1.029 (1.023–1.036) | <.001 | 1.023 (1.016–1.029) | <.001 | 1.011 (1.004–1.018) | .002 |
| Increase 5 mg/g | 1.156 (1.120–1.193) | <.001 | 1.119 (1.083–1.155) | <.001 | 1.056 (1.021–1.092) | .002 | ||
| All-cause mortality | Increase 1 mg/g | 185/14 602 | 1.076 (1.058–1.095) | <.001 | 1.067 (1.048–1.086) | <.001 | 1.063 (1.043–1.083) | <.001 |
| Increase 5 mg/g | 1.445 (1.323–1.557) | <.001 | 1.382 (1.263–1.512) | <.001 | 1.357 (1.237–1.488) | <.001 | ||
| . | . | . | Unadjusted . | Model 1 . | Model 2 . | |||
|---|---|---|---|---|---|---|---|---|
| Outcome . | . | Events/n . | HR (95% CI) . | P value . | HR (95% CI) . | P value . | HR (95% CI) . | P value . |
| Progression to CKM stage 4 | Increase 1 mg/g | 1646/14 602 | 1.029 (1.023–1.036) | <.001 | 1.023 (1.016–1.029) | <.001 | 1.011 (1.004–1.018) | .002 |
| Increase 5 mg/g | 1.156 (1.120–1.193) | <.001 | 1.119 (1.083–1.155) | <.001 | 1.056 (1.021–1.092) | .002 | ||
| All-cause mortality | Increase 1 mg/g | 185/14 602 | 1.076 (1.058–1.095) | <.001 | 1.067 (1.048–1.086) | <.001 | 1.063 (1.043–1.083) | <.001 |
| Increase 5 mg/g | 1.445 (1.323–1.557) | <.001 | 1.382 (1.263–1.512) | <.001 | 1.357 (1.237–1.488) | <.001 | ||
Model 1 was adjusted by age and gender. Model 2 was adjusted by age, gender, hypertension, diabetes, non-HDL cholesterol, eGFR and administration of statins. UACR, urinary albumin-to-creatinine ratio.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
